Skip to main content

New medicines advice for NHS Wales

Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for three medicines.

  • Cariprazine (Reagila®) is recommended to treat schizophrenia in adults. Cariprazine belongs to a group of medicines called antipsychotics.
  • Mercaptamine bitartrate (Procysbi®) is recommended to treat nephropathic cystinosis in children and adults. Cystinosis is a disease affecting how the body functions, with an abnormal accumulation of the amino acid cystine in various organs of the body. Build-up of cystine damages the kidneys. Procysbi® is a medicine that reacts with cystine to decrease its level within cells. When treatment is started early, it delays the development of kidney damage.
  • Teriflunomide (AUBAGIO®) is recommended to treat relapsing-remitting multiple sclerosis in children and young people aged 10 years to 17 years.

AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.

Follow AWTTC: